Medicine and Dentistry
Cell Death
100%
Proteasome
100%
Bortezomib
84%
Programmed Cell Death
53%
Cancer Cell
38%
Death Receptor
30%
Caspase 8
23%
Prostate Cancer
23%
Multiple Myeloma
15%
Neoplasm
15%
Clinical Trial
15%
Castration Resistant Prostate Cancer
7%
Disease Exacerbation
7%
Epithelial Cell
7%
Angiogenesis
7%
Patient Population
7%
Tumor Microenvironment
7%
Xenograft
7%
Benzyloxycarbonylleucylleucylleucinal
7%
Cytokine
7%
Tumor Cell
7%
Prostate Cancer Cell Line
7%
Enzyme Activity
7%
Malignant Neoplasm
7%
Ubiquitin
7%
Fas Ligand
7%
Cell Signaling Pathway
7%
Immunology and Microbiology
Cell Death
100%
Proteasome
100%
Programmed Cell Death
53%
Cancer Cell
38%
Death Receptor
30%
Caspase
23%
Multiple Myeloma
15%
Prostate
15%
TRAIL
15%
Xenograft
7%
Angiogenesis
7%
Enzyme Activity
7%
Cytokine
7%
Prostate Cancer Cell Line
7%
Drug Concentration
7%
Fas Ligand
7%
Tumor Cell
7%
Ubiquitins
7%
Pharmacology, Toxicology and Pharmaceutical Science
Proteasome
100%
Bortezomib
84%
Prostate Cancer
30%
Malignant Neoplasm
30%
Death Receptor
30%
Caspase 8
23%
Neoplasm
23%
Multiple Myeloma
15%
Clinical Trial
15%
Drug Concentration
7%
Cytokine
7%
Disease Exacerbation
7%
Tumor Microenvironment
7%
Benzyloxycarbonylleucylleucylleucinal
7%
Ubiquitin
7%
Fas Ligand
7%
Castration Resistant Prostate Cancer
7%